Dashboard
1
Poor Management Efficiency with a low ROCE of 3.19%
- The company has been able to generate a Return on Capital Employed (avg) of 3.19% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 0.43% and Operating profit at -1.21% over the last 5 years
3
Negative results in Mar 25
4
With ROE of 2.67%, it has a attractive valuation with a 1.32 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,053 Million (Small Cap)
50.00
NA
2.35%
-0.21
2.67%
1.32
Revenue and Profits:
Net Sales:
476 Million
(Quarterly Results - Jun 2025)
Net Profit:
19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.27%
0%
6.27%
6 Months
4.67%
0%
4.67%
1 Year
-7.7%
0%
-7.7%
2 Years
-20.21%
0%
-20.21%
3 Years
-29.58%
0%
-29.58%
4 Years
31.13%
0%
31.13%
5 Years
31.88%
0%
31.88%
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.43%
EBIT Growth (5y)
-1.21%
EBIT to Interest (avg)
-11.55
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.84
Tax Ratio
25.83%
Dividend Payout Ratio
112.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.19%
ROE (avg)
1.97%
Valuation key factors
Factor
Value
P/E Ratio
50
Industry P/E
Price to Book Value
1.32
EV to EBIT
28.54
EV to EBITDA
14.89
EV to Capital Employed
1.41
EV to Sales
1.37
PEG Ratio
NA
Dividend Yield
2.35%
ROCE (Latest)
4.93%
ROE (Latest)
2.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
475.70
470.70
1.06%
Operating Profit (PBDIT) excl Other Income
45.80
43.10
6.26%
Interest
2.60
2.50
4.00%
Exceptional Items
-0.10
0.20
-150.00%
Consolidate Net Profit
18.70
15.70
19.11%
Operating Profit Margin (Excl OI)
49.90%
44.70%
0.52%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 1.06% vs -2.04% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 19.11% vs 115.07% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,021.90
2,311.90
-12.54%
Operating Profit (PBDIT) excl Other Income
186.50
232.50
-19.78%
Interest
14.30
16.10
-11.18%
Exceptional Items
-3.10
-54.30
94.29%
Consolidate Net Profit
66.10
58.30
13.38%
Operating Profit Margin (Excl OI)
46.40%
60.10%
-1.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -12.54% vs -2.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 13.38% vs 20.70% in Dec 2023
About Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. 
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






